OBI Pharma, Inc. (4174.TWO)

59.20 +0.60 (+1.02%) At close: 01:30PM CST

OBI Pharma, Inc.

No. 508, Sec. 7
6th Floor Zhongxiao E. Rd. Nangang District
Taipei 115
Taiwan
886 2 2786 6589
https://www.obipharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Ming-Tien Lai	Chief Scientific Officer	7.73M	N/A	N/A
Mr. Cheng-En Tsai	VP of Medical Department & Director	7.38M	N/A	N/A
Dr. Heidi Wang Ph.D.	Chief Executive Officer	N/A	N/A	N/A
Mr. Colin Kao	CFO, Accounting Supervisor & Corporate Governance Supervisor	N/A	N/A	N/A
Mr. Po-Jen Chang	Director of Human Resources & Administration	N/A	N/A	N/A
Ms. Sharon Lee	Director of Public Affairs	N/A	N/A	N/A
Mr. Kevin P. Poulos	Chief Business Officer	N/A	N/A	1959
Dr. Wayne Saville M.D.	Chief Medical Officer	N/A	N/A	N/A
Dr. Dong Xu Ph.D.	Senior Vice President of Biostatistics & Data Management	N/A	N/A	N/A
Mr. Chun-Hung Chou	Vice President of Chemical Pharmacy and R&D Office	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.

Description

OBI Pharma, Inc., a biopharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. It offers Adagloxad Simolenin (OBI-822), a breast cancer active immunity anti-cancer drug for generating antibody against tumor surface antigen Globo H; OBI-833, an immunity anti-cancer drug for the treatment of lung cancer; OBI-866 SSEA-4, an active immune-oncology drug; OBI-888, a Globo H monoclonal antibody; OBI-999, an antibody drug conjugate; OBI-3424, a micromolecule chemotherapy prodrug; and OBI-858, a botulinum toxin, as well as OBI-898, OBI-998, and COVID-19 BCVax drugs. The company was founded in 2002 and is headquartered in Taipei, Taiwan.

Corporate governance

OBI Pharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.